RZLT

Rezolute Inc.

NASDAQ

Add Alert

RZLT

Rezolute Inc.

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older Newer

saigai

05/06/22 9:50 PM

Post #195

rzlt insider buys
Rezolute Director Gil Labrucherie Buys $199,997.80
Rezolute SVP Brian Kenneth Roberts Buys $79,997.60

saigai

05/02/22 7:35 AM

Post #194

great data and then.. the offering.. shoot me

saigai

04/29/22 10:54 AM

Post #193

well the numbers are out on sunday.. holding 4k shares...into the news....

saigai

04/25/22 9:47 AM

Post #192

idont care if im talking to myself.. this is going to 40 bucks.. in the near term.. so to all the criminals out there gfy

saigai

04/25/22 8:23 AM

Post #191

soon they will be sending hit men to your door ....belly up and pay retail criminals mofos

saigai

04/25/22 7:46 AM

Post #190

pre mkt down 10percent on 1 share traded...must be getting real close to the kaboom because the knives are out..

saigai

04/21/22 10:36 AM

Post #189

adding a few everyday...

saigai

04/14/22 1:06 PM

Post #188

from last nesw release im tellin you kaboom is coming

REDWOOD CITY, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced positive data from its Phase 2b RIZE study of RZ358. The data demonstrated the safety and tolerability of RZ358 in patients with congenital hyperinsulinism, as well as highly significant improvements in hypoglycemia. The RIZE study results will be presented in an oral presentation at an upcoming medical congress in 2Q 2022, followed by a conference call hosted by the Company to discuss the data.

“We are very encouraged by the results and are looking forward to moving the program into Phase 3,” said Nevan Charles Elam, CEO and Founder of Rezolute. Mr. Elam continued, “We are very grateful to the patients, their families, patient advocacy organizations, and the investigators who participated in this study. I also appreciate the tremendous dedication of the Rezolute team, who are mission driven to develop an innovative treatment option for this debilitating condition.”

saigai

04/11/22 9:29 PM

Post #187

no buying into the close.. oh well. the next couple of days could get dicey

saigai

04/07/22 11:24 AM

Post #186

they drop it i buy . just 10 at a time . it adds up.

saigai

04/06/22 2:57 PM

Post #185

institutional investors snacking on the bid. sooner or later that cant live there..lock em up folks

saigai

04/04/22 4:01 PM

Post #184

chit close thought we would have a better day. its coming but this is the top until the data

saigai

04/04/22 12:13 PM

Post #183

where is everyone.

saigai

04/04/22 10:50 AM

Post #182

everytime the criminals drop it i buy more.

saigai

04/04/22 9:22 AM

Post #181

strap in folks we are going on a wild one

saigai

04/01/22 4:25 PM

Post #180

strong close ....zip code changer in the making

saigai

03/31/22 4:28 PM

Post #179

from nasdaq website follow the money

https://www.nasdaq.com/market-activity/stocks/rzlt/institutional-holdings

saigai

03/31/22 4:07 PM

Post #178

and another 500 at the buzzer..this is my waterloo and exrof. i need one or the other or my trading days are OVER!!! glta.. i dont think i ever believed more strongly in than i do these 2 companies good lucky to anyone with me!!!

saigai

03/31/22 3:45 PM

Post #177

i wish there was someone else out there watching this tape. this is the most incredible price action/criminality ive seen in a while..but i am gonna be here for the big big money or where the dunce cap. time will tell

saigai

03/31/22 2:57 PM

Post #176

i know im talking to myself but this is the weirdest price action ive seen in a very long time.. not day to day but during the day.. something is cookin here. bought a few more ..cant help myself

saigai

03/31/22 12:56 PM

Post #175

another jumpy day with little price movement. i dont know if it short covering delicately or institutional accumulation with saint like patience. holding for what should be off the charts data

saigai

03/29/22 9:56 AM

Post #174

well the bid ask is really jumpy but the trend is not good so no more avg down. just holding for the data

saigai

03/28/22 3:26 PM

Post #173

avg down a little more waiting on the data

saigai

03/25/22 8:34 AM

Post #172

i dont think this board gonna stay quiet for much longer. i hope

saigai

03/23/22 1:59 PM

Post #171

run you mofo

Mushyheaded Free

08/01/21 11:15 PM

Post #170

Inc Genexine owns over 1000% of Rezolute Inc.

At least, according to Wall Street Zen [as of today, August 1, 2021]. I've seen stocks have over 100% shares owned by insiders... even 200%. But this? Wtf?

Can anyone explain this? Lmao.

screenshot: https://imgur.com/gallery/n0wUVa0

Renee

11/09/20 9:16 AM

Post #169

RZLT moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

daleb2130

10/17/20 9:55 AM

Post #168

Re: #167: @TrendTrade2016 - Got mine...sold all at 21.00

I sold 50% of mine at 22.50. I still think there is a reason they wanted to go to the Nasdaq and needed to raise 40 million. I expect big news soon.. Plus all those insider buys since the beginning of July. But who knows.

TrendTrade2016 PremiumMember

10/17/20 5:05 AM

Post #167

Re: #166: @daleb2130 - Not yet on Ameritrade. . Just showing up

Got mine...sold all at 21.00

daleb2130

10/15/20 9:07 AM

Post #166

Re: #165: @TrendTrade2016 - Did you get you shares from the split

Not yet on Ameritrade. . Just showing up as numbers.

The "Think or Swim" app shows it's trading with Level 2 and Times and sales as RZTLD

TrendTrade2016 PremiumMember

10/15/20 5:53 AM

Post #165

Re: #164: @daleb2130 - Got to be some good news coming after

Did you get you shares from the split

daleb2130

10/14/20 6:12 PM

Post #164

Re: #163: @TrendTrade2016 - wow 24 bucks...give me my shares!!

Got to be some good news coming after the RS. I thought this might sell off bit. But, so far it doesn't look like it..

TrendTrade2016 PremiumMember

10/14/20 6:03 PM

Post #163

wow 24 bucks...give me my shares!!

OptimusPrime555 Free

10/10/20 7:08 PM

Post #162

Re: #161: @TrendTrade2016 - Like I said they want this on he

Low volume GARBAGE! REVERSE SPLIT!!!

TrendTrade2016 PremiumMember

10/10/20 6:49 AM

Post #161

Like I said they want this on he nasdaq...now we watch very closely!!!

Renee

10/09/20 5:36 PM

Post #160

RZLT one for 50 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

mick

09/22/20 2:16 PM

Post #159

Re: #158: @daleb2130 - It looks like insider Handok is buying 125,000

daleb2130

09/21/20 12:02 PM

Post #158

Re: #157: @mick - THANK YOU Rezolute Inc (QB) (RZLT)

It looks like insider Handok is buying 125,000 every day now. I wonder what their end game is? Higher volume today so I'm assuming we will see another Form 4 Wednesday

https://www.otcmarkets.com/filing/html?id=14398925&guid=Ye86Up5mwFygKth

https://www.otcmarkets.com/filing/html?id=14397065&guid=Ye86Up5mwFygKth

mick

09/15/20 8:16 PM

Post #157

Re: #156: @daleb2130 - RZLT And another 125,000 buy by Handok @.4908

THANK YOU Rezolute Inc (QB) (RZLT)
0.45 ? 0.0115 (2.62%)
Volume: 246,828 @09/15/20 3:56:57 PM EDT
Bid Ask Day's Range
0.4265 0.4629 0.44 - 0.4629
RZLT Detailed Quote

daleb2130

09/15/20 8:12 PM

Post #156

Re: #155: @mick - #2 Rezolute Inc (QB) (RZLT)

RZLT

And another 125,000 buy by Handok @.4908

https://www.otcmarkets.com/filing/html?id=14390766&guid=S8o6UqTA_zbcwyh

mick

09/14/20 2:15 PM

Post #155

Re: #153: @mick - Rezolute Inc (QB) (RZLT)

#2 Rezolute Inc (QB) (RZLT)
0.4355 ? -0.0405 (-8.51%)
Volume: 333,742 @09/14/20 1:50:02 PM EDT
Bid Ask Day's Range
0.42 0.4355 0.4 - 0.4994
RZLT Detailed Quote

mick

09/14/20 2:15 PM

Post #154

Re: #151: @daleb2130 - Yup. Thanks for those .41's whoever panicked. Large

Rezolute Inc (QB) (RZLT)
0.4355 ? -0.0405 (-8.51%)
Volume: 333,742 @09/14/20 1:50:02 PM EDT
Bid Ask Day's Range
0.42 0.4355 0.4 - 0.4994
RZLT Detailed Quote

mick

09/14/20 2:15 PM

Post #153

Re: #151: @daleb2130 - Yup. Thanks for those .41's whoever panicked. Large

Rezolute Inc (QB) (RZLT)
0.4355 ? -0.0405 (-8.51%)
Volume: 333,742 @09/14/20 1:50:02 PM EDT
Bid Ask Day's Range
0.42 0.4355 0.4 - 0.4994
RZLT Detailed Quote

TrendTrade2016 PremiumMember

09/08/20 5:30 PM

Post #152

dont get shook, its all games....onward and upward to 70c next as we approach the nasdaq

daleb2130

09/08/20 4:05 PM

Post #151

Re: #150: @kanonman - BOOM!!! back above.50

Yup. Thanks for those .41's whoever panicked. Large volume compared to normal so om assuming we will see another form 4 or 2 buys by Thursday by the insiders.

kanonman

09/08/20 3:58 PM

Post #150

Re: #149: @daleb2130 - I just bought more myself. Im going to

BOOM!!! back above.50

daleb2130

09/08/20 1:07 PM

Post #149

Re: #148: @kanonman - another block of 125000 bought by insiders today.

I just bought more myself. Im going to keep buying if they do. Assuming they are again today.

kanonman

09/08/20 11:14 AM

Post #148

another block of 125000 bought by insiders today. why the drop?

TrendTrade2016 PremiumMember

09/05/20 6:42 AM

Post #147

precision trading...called every move to perfection to .65c...its all there...target by target....stock is in a sideways trend now!!

daleb2130

09/04/20 7:39 PM

Post #146

Re: #145: @kanonman - more churn today...

2 more Hadcock buys for 125,000 shares each. One at .58, another at .48.

Older Newer

Rezolute Inc. (RZLT)

Followers	17	Posters	43
Posts (Today)	0	Posts (Total)	253
Created	01/20/13	Type	Free
Moderators

AntriaBio, Inc.
890 Santa Cruz Avenue
Menlo Park, CA 94025
P: (650) 223-5441
info@antriabio.com

Reverse Merger

Jan 7, 2013 - AntriaBio, Inc., a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the acquisition of the significant assets of PR Pharmaceuticals, Inc. and its intention to become a publicly traded company through a merger.

"AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery," said Nevan Elam, AntriaBio's President and CEO. "AB101 may offer significant advantages over basal insulin products sold by Sanofi-Aventis and Novo Nordisk, which together sell more than $7B annually."

AntriaBio's lead diabetes product candidate, AB101, is a once-a-week injectable basal insulin that is currently in preclinical development. AB101 is administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia.

The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level which supplements the effects of endogenous and exogenous insulin and complements the effects of orally administered hypoglycemic agents. AB101 has the potential to be a clearly differentiated product that represents a significant advance in basal insulin delivery.

AB101's long duration of action is the result of our ability to PEGylate insulin and then encapsulate it into poly-lactic, poly-glycolic (PLGA) microspheres. Currently available PEGylated biomolecules typically use large molecular weight PEG chains to decrease clearance and therefore reduce injection frequency. However, we use a very small molecular weight PEG for AB101 to modify the solubility of insulin and permit encapsulation of the drug into a biodegradable polymer.

After injection, the PEGylated insulin is slowly released at the injection site as the polymer microspheres are broken down by simple hydrolysis. Not only is our technology is unique, but also AB101 does not contain any new excipients and regulatory authorities have already approved numerous products using PEG or biodegradable polymers.

In addition to the proprietary technology for PEGylation of insulin and incorporation of the PEGylated insulin into biodegradable polymers, we have licensed proprietary microparticle manufacturing technology. The microsphere manufacturing process ensures production of a very tight particle size distribution with uniformly small microparticles. This is important to improve manufacturing efficiency and yields as well as to facilitate patient comfort by producing microspheres that can be injected through 25 gauge or smaller needles.

AntriaBio Appoints Two Industry Leaders to its Management Team

Menlo Park, CA - February 19th, 2013 - AntriaBio, Inc. is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D, as AntriaBio's Chief Scientific Officer.

Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited, a medical device company based in Europe. Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.

Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia, Latin America and the Middle East. Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University.

Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009, Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013, AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.

"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe, Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.

Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than 8 patents.

Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation, now part of Abbott Vascular. Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine. Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany.